According to the Millennium Research Group, the skin rejuvenation market is expected to grow annually by 18 percent, resulting in a $239 million industry by 2010, with approximately 4.4 million procedures performed per year by 2010.
"The Affirm CO2 targets a large and growing market of consumers for whom age is not an impediment to vitality or a youthful appearance," Davin said. "In a country where 12,000 people turn 50 every day, and the population over the age of 55 is expected to grow 60% over the next 20 years, we believe the market opportunity for Cynosure is significant."
"With power up to 30 watts and an adjustable pulse duration between 0.2 and 2 milli seconds, Affirm CO2 offers the versatility of performing a light to aggressive treatment with a single laser," said Bruce Katz, M.D., Clinical Professor of Dermatology at The Mount Sinai School of Medicine, Director of the Cosmetic Surgery & Laser Clinic at Mount Sinai Medical Center and Director of the Juva Skin & Laser Center in New York. "Another important benefit is the range of scanning options, which enable users not only to shorten treatment time, but to provide uniform coverage across the entire treatment area."
Initial U.S. shipments of Affirm CO2 are expected to begin in the third quarter of 2008.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that
are used by physicians and other practitioners to perform non-invasive and
minimally invasive procedures to remove hair, treat vascular lesions,
rejuvenate skin through the treatment of shallow vascular and pigmented
lesions, laser lipolysis and temporarily reduce the appearance of
cellulite. Cynosure's products include a broad range of laser and other
light-based energy sources, including Alexandrit
|SOURCE Cynosure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved